Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer | Zendy

Neil M. Iyengar | Zendy; Lillian M. Smyth | Zendy; Diana Lake | Zendy; Ayca Gucalp | Zendy; Jasmeet Singh | Zendy; Tiffany A. Traina | Zendy; Patricia DeFusco | Zendy; Monica Fornier | Zendy; Shari Goldfarb | Zendy; Komal Jhaveri | Zendy; Shanu Modi | Zendy; Tiffany A. Troso-Sandoval | Zendy; Sujata Patil | Zendy; Gary A. Ulaner | Zendy; Maxine S. Jochelson | Zendy; Larry Norton | Zendy; Clifford A. Hudis | Zendy; Chau T. Dang | Zendy

Open Access

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Author(s) -

Neil M. Iyengar,

Lillian M. Smyth,

Diana Lake,

Ayca Gucalp,

Jasmeet Singh,

Tiffany A. Traina,

Patricia DeFusco,

Monica Fornier,

Shari Goldfarb,

Komal Jhaveri,

Shanu Modi,

Tiffany A. Troso-Sandoval,

Sujata Patil,

Gary A. Ulaner,

Maxine S. Jochelson,

Larry Norton,

Clifford A. Hudis,

Chau T. Dang

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.16211

Subject(s) - pertuzumab , trastuzumab , medicine , metastatic breast cancer , oncology , clinical endpoint , breast cancer , gemcitabine , lapatinib , clinical trial , cancer

Key Points Question Is dual anti–human epidermal growth factor receptor 2 ( ERBB2, formerly HER2 ) therapy with trastuzumab and pertuzumab effective after prior pertuzumab-based therapy for ERBB2 -positive metastatic breast cancer? Findings In this phase 2 clinical trial, treatment with gemcitabine, trastuzumab, and pertuzumab after prior pertuzumab-based therapy for ERBB2 -positive metastatic breast cancer was associated with a 3-month progression free survival rate of 73.3%. Treatment was well tolerated with no occurrences of symptomatic left ventricular systolic dysfunction. Meaning In this study, dual anti- ERBB2 therapy with trastuzumab and pertuzumab after prior pertuzumab exposure was active and well tolerated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research